MediPrint Ophthalmics Announces Promising Phase 2b Results for Drug-Eluting Contact Lens in Glaucoma Management
MediPrint Ophthalmics has revealed positive findings from its Phase 2b clinical trial for LL-BMT1, a 3D-printed, drug-eluting contact lens designed to treat mild to moderate glaucoma. These results, presented by Ian Ben Gaddie, OD, FAAO, at the American Academy of Optometry’s annual meeting in Indianapolis, showcase the potential of LL-BMT1 as an effective alternative for glaucoma management, while also enhancing comfort for contact lens users.
Key Trial Outcomes: Effective IOP Reduction with Minimal Dosing
The LL-BMT1 lens, which combines bimatoprost with hyaluronic acid for sustained release and added moisture, demonstrated efficacy comparable to bimatoprost 0.01% eye drops. Notably, the 32-µg dose of LL-BMT1 required only six lens insertions over three weeks—an 86% reduction in treatment frequency compared to daily eye drops. This reduced dosing frequency holds promise for improving patient compliance and long-term outcomes in glaucoma care.
“LL-BMT1 represents a potential major step forward in glaucoma care, offering an effective, less burdensome alternative to daily eye drops and a less invasive option to laser or surgical modalities,” said Dr. Ian Ben Gaddie, OD, FAAO. “These results are truly encouraging for both patients and practitioners seeking better treatment options.”
Enhanced Comfort and Dry Eye Relief
Beyond its effectiveness in lowering intraocular pressure (IOP), LL-BMT1 incorporates hyaluronic acid to improve comfort for contact lens wearers by reducing dry eye symptoms. The study showed that patients experienced a 38% improvement in comfort and a 40% reduction in dry eye symptoms while using LL-BMT1, suggesting the lens could support extended wear and potentially weekly use.
Strong Safety Profile and Patient-Friendly Design
The Phase 2b trial also confirmed the strong safety profile of LL-BMT1. MediPrint reports that the preservative-free lenses were well tolerated, with no serious adverse events reported among participants.
“Our clinical study results demonstrate that LL-BMT1 could offer a highly effective and patient-friendly alternative to daily eye drops, especially for glaucoma patients who struggle with adherence,” said Praful Doshi, Founder and CEO of MediPrint Ophthalmics. “We’re excited to advance this technology through phase 3 trials, aiming to set a new standard in glaucoma care and address comfort needs for millions who discontinue contact lenses due to discomfort.”
Future Plans: Two Key Programs for 2025
Following these promising Phase 2b results, MediPrint plans to launch two major programs in 2025:
1. Comfort Enhancement Program: Utilizing hyaluronic acid in daily disposable lenses to improve wearability and reduce discomfort.
2. Phase 3 Clinical Study for LL-BMT1: Advancing LL-BMT1 for glaucoma treatment with the goal of bringing the product to market by 2025.
The Phase 2b results mark a major step forward in glaucoma care and the broader field of ocular drug delivery, underscoring MediPrint’s commitment to providing innovative, patient-centered solutions for the eye care community.
